Cytomegalovirus (CMV), which is also commonly known as the common herpes virus infection, has generated steady demand for new and improved treatment options owing to its easy communicability through body fluids such as saliva, blood, or breast milk. Moreover, easy transmission from pregnant women to their children is also creating a rising demand for CMV treatments.
Rising incidences of cytomegalovirus infections, growing awareness about the disease, rapid drug development efforts, development of healthcare infrastructure, and government support are key factors that are anticipated to boost the rise of the CMV infection treatment market.
Growing Adoption of Valganciclovir Displaying Improved Results
Earlier, in cases of cutaneous cytomegalovirus infections, treatments usually included intravenous administration of drugs such as Foscarnet sodium and Ganciclovir. However, a compromised immune system necessitated a long-term treatment procedure. Such extensive intravenous administration of these drugs are known increase the risk of infections, while adversely affecting the quality of life along with long term dependence on cost-prohibitive nursing care.
However, with the rapidly increasing adoption of the new oral medication Valganciclovir, allowed extensive improvement in the patient’s condition within six weeks of medicated therapy, with constant reduction in amount of medication needed, displaying a marked improvement in the treatment for CMV conditions.
Hospital CMV Treatments are Driven by Infections in Infants
Congenital CMV has been observed to affect children up to five years of age the most, with nearly three fourths of all hospitalizations and deaths due to CMV belonging to this demographic. Children suffering from symptomatic congenital CMV requires complex surgical and medical care, for a long term process, which is usually expensive on the patients and local healthcare infrastructure.
As per studies by the International Network of Pediatric Surveillance Units, have found that vaccinations have found a high rate of success when administered to healthy women between 15 to 25 years. Moreover, the low force of infection and relatively lesser basic reproductive number of CMV has resulted in a significantly lower requirement of vaccination rates to achieve the elimination of the ailment.
The study provides an indication for cytomegalovirus treatment drug developers towards the opportunity available in the field of vaccine development, and future healthcare policies in regards to priority by healthcare organizations. On the other hand, the limitations of accuracy on data from hospital discharges, necessitates the need for further research in the field.
Cytomegalovirus Retinitis Attracts the Development of New Drugs
Cytomegalovirus retinitis is one of the most commonly observed complication arising during incidences of CMV, which is increased in cases where the patient is suffering from HIV. Currently, the highly active antiretroviral therapy (HAART) is a popular treatment method with fair success rates towards preventing or reducing the effect of CMV retinitis, in addition to drugs including Ganciclovir, Foscarnet, Cidofovir, and Fomivirsen. However, the severe and long term nature of toxicity resulting from the usage of these drugs has created demand for new drug variants for the treatment CMV conditions.
For example, in early 2018, Shire Plc, a subsidiary of Takeda Pharmaceutical Company Ltd. announced that its phase 3 investigational Maribavir drug had received breakthrough therapy designation by the FDA. The drug works by disrupting the egress and DNA packaging of the virus, instead of affecting the DNA replication mechanism of the virus, unlike other conventional drug options. This resulted in higher rate of disease elimination, in addition to also minimizing toxicity and side effects such as myelosuppression.
Tomeglovir also known as BAY-38-4766 is another new drug for treating CMV retinitis – a non-nucleoside antiviral, produced by MedKoo Biosciences Inc., which has shown positive results in animal trials including immunocompromised guinea pigs, and is expected to go into human trials in the near future, providing opportunities for healthcare professionals in terms of treatment options.
Download Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8665
